Skip to main content

Table 3 Univariate analysis of prognostic factors

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Prognostic factornMedian OS (months)p value
Sex
 Male756.50.052
 Female2910.6 
ECOG PS
 0937.30.038
 1, 2115.2 
Age
  ≥ 701270.334
  < 70927.3 
Pancreatic resection
 Yes3170.319
 No738 
First-line therapy duration
  ≤ 4 months1970.459
  > 4 months857.3 
Liver metastasis
 Yes726.50.054
 No329.9 
CEA (ng/mL)
  ≤ 10699.9< 0.001
  > 10356.2 
CA19–9 (IU/mL)
  ≤ 1000577.50.621
  > 1000477 
Alb (g/dL)
  < 3.54060.014
  ≥ 3.5649.4 
CRP (mg/dL)
  ≤ 0.163511.6< 0.001
  > 0.16695.9 
GPS
 Low (0)4410.6< 0.001
 High (1, 2)606 
NLR
  ≤ 5.0968.7< 0.001
  > 5.084.6 
  1. Alb albumin, CA19–9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, CRP C-reactive protein, ECOG PS Eastern Cooperative Oncology Group performance status, GPS Glasgow prognostic score, NLR neutrophil-to-lymphocyte ratio